



The Board of Directors appoints Leon Van Rompay as CEO ad interim

Liege, Belgium, 4 February 2021 – 7:30 CET – Meeting this Wednesday evening, the Board of Directors of Mithra (Euronext Brussels: MITRA), a company dedicated to women's health, heard François Fornieri following his indictment in the context of a file relating to functions he previously held in a company not related to Mithra.

At the end of this exchange, the Board of Directors accepted that François Fornieri take a step back as CEO, until further notice, for a maximum of 12 months. In doing so, François Fornieri is laying down any executive function at Mithra.

As a result hereof, the Board of Directors has decided to appoint Leon Van Rompay as CEO ad interim until further notice. François Fornieri remains at the disposal of the CEO ad interim.

Leon Van Rompay has more than 40 years of experience in the international pharmaceutical industry. After holding various management positions in several big pharma companies (Bayer, Glaxosmithkline, Zambon), Leon Van Rompay created Docpharma in 1999, a company specializing in marketing generic drugs. Docpharma got listed on the stock exchange (Euronext), and was successfully sold to the Matrix Group in 2005.

Leon Van Rompay has been actively involved in the management of Uteron Pharma, the predecessor of Mithra and strengthened with his international experience and industry expertise, he will support the company to meet this year's important milestones.

The Board of Directors also relieved Christophe Maréchal of his temporary assignment so that he can again devote himself to the financial management of Mithra.

With this decision, the Board of Directors is convinced that the company has all the necessary resources and skills to carry out its numerous projects.

For more information, please contact:

Jean-Manuel Fontaine (IRO) : +32 476 96 54 59- investorrelations@mithra.com

Maud Vanderthommen (Press) : +32 473 58 61 04 - press@mithra.com

About Mithra

Mithra (Euronext: MITRA) is a Belgian biotech company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Its three lead development candidates are built on Mithra's unique native estrogen platform, Estetrol (E4): Estelle®, a new era in oral contraception, PeriNesta®, the first complete oral treatment targeting perimenopause and Donesta®, the next-generation hormone therapy. Mithra also develops and manufactures complex therapeutics in the areas of contraception, menopause and hormone-dependent cancers. It offers partners a complete spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. Active in more than 100 countries around the world, Mithra has an approximate headcount of 300 staff members and is headquartered in Liège, Belgium. www.mithra.com

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.